ASMB

Assembly Biosciences, Inc.

15.37 USD
+0.12 (+0.79%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Assembly Biosciences, Inc. stock is up 10.58% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 13 June’s closed higher than May.

About Assembly Biosciences, Inc.

Assembly Biosciences, Inc. discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.